STEMI patients in the TRITON-TIMI 38 ( Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis In Myocardial Infarction 38 ) were randomized to prasugrel or clopidogrel on presentation if primary PCI was intended or later during secondary PCI .